There are several clinical trials using autologous infusion of expanded Treg cells (also combined with IL-2 injections) during early and late phases of ALS disease in patients with varying rates of disease progression (trial #ID: NCT03241784, NCT04055623). The gene discussed is IL2; the disease is amyotrophic lateral sclerosis.